It is time to end our love affair with short-acting β(2)-agonists in asthma

In this issue of ERJOR, Noorduyn et al. add data to the growing literature showing that SABA overuse in asthma is both common and associated with severe exacerbations. It is time to take note and act to tackle this global issue. https://bit.ly/3BfwhfS

Detalles Bibliográficos
Autores principales: Crooks, Michael G., Faruqi, Shoaib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574554/
https://www.ncbi.nlm.nih.gov/pubmed/36267894
http://dx.doi.org/10.1183/23120541.00353-2022
Descripción
Sumario:In this issue of ERJOR, Noorduyn et al. add data to the growing literature showing that SABA overuse in asthma is both common and associated with severe exacerbations. It is time to take note and act to tackle this global issue. https://bit.ly/3BfwhfS

Ejemplares similares